Price
CHART BY
Frequently asked questions
What is Co-Diagnostics's market capitalization?
The market capitalization of Co-Diagnostics is $5.13M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Co-Diagnostics?
Co-Diagnostics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -28.73. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Co-Diagnostics's stock?
Currently, 2 analysts cover Co-Diagnostics's stock, with a consensus target price of $45.00. Analyst ratings provide insights into the stock's expected performance.
What is Co-Diagnostics's revenue over the trailing twelve months?
Over the trailing twelve months, Co-Diagnostics reported a revenue of $507.89K.
What is the EBITDA for Co-Diagnostics?
Co-Diagnostics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$34.33M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Co-Diagnostics?
Co-Diagnostics has a free cash flow of -$31.81M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Co-Diagnostics have, and what sector and industry does it belong to?
Co-Diagnostics employs approximately 132 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Co-Diagnostics's shares?
The free float of Co-Diagnostics is 1.92M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.13M
- EPS (TTM)
- -28.73
- Free Float
- 1.92M
- Revenue (TTM)
- $507.89K
- EBITDA (TTM)
- -$34.33M
- Free Cashflow (TTM)
- -$31.81M
Analyst Ratings
The price target is $45.00 and the stock is covered by 2 analysts.
Buy
0
Hold
2
Sell
0
Information
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
- Employees
- 132
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- CODX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet